

PRIOR AUTHORIZATION POLICY

POLICY: Hemophilia – Eptacog Products

- NovoSeven® RT (Coagulation Factor VIIa [recombinant] for intravenous use – Novo Nordisk)

APPROVAL DATE: 10/02/2019

OVERVIEW

NovoSeven RT is indicated for treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII deficiency, and Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.¹ It is also indicated for treatment of bleeding episodes and perioperative management in adults with acquired hemophilia. It is produced by recombinant technology in baby hamster kidney cells. Exogenous viruses are removed through a chromatographic purification process. No human serum or other proteins are used in the production or formulation of NovoSeven RT. The half-life of NovoSeven RT is short (approximately 2 to 3 hours in patients with hemophilia A, hemophilia B, or congenital Factor VII deficiency), therefore frequent dosing is often required.

Disease Overview

Hemophilia A is an X-linked bleeding disorder caused by a deficiency in coagulation Factor VIII.² The birth prevalence of hemophilia A in the US is approximately 1:6,500 live male births. **Hemophilia B**, caused by deficiency in Coagulation Factor IX, is clinically indistinguishable from hemophilia A and is also inherited in an X-linked manner.³ The birth prevalence is approximately 1:30,000 live male births. Bleeding episodes are treated with plasma-derived or recombinant Factor VIII or Factor IX concentrates. These agents are also given prophylactically for individuals with severe disease.

Approximately 30% of patients with severe hemophilia A and 1 to 3% of patients with severe hemophilia B develop alloimmune inhibitors (antibodies) to Factor VIII or Factor IX concentrate.^{2,3} In **acquired hemophilia A**, individuals who were not born with hemophilia develop inhibitors to endogenous Factor VIII.⁴ Certain conditions, including cancer, lupus erythematosus, and other autoimmune disorders, may predispose patients to development of acquired hemophilia A. In both acquired and congenital hemophilia, presence of inhibitors at high titers makes the factor replacement ineffective, and alternative "bypassing" agents are needed to promote hemostasis. Examples of commercially available bypassing agents include NovoSeven RT, as well as FEIBA® (anti-inhibitor coagulant complex for intravenous use).⁵ Hemlibra® (emiczumab-kxwh for subcutaneous use) is a monoclonal antibody that mimics the action of Factor VIII and therefore is only indicated in hemophilia A.

Glanzmann's thrombasthenia (GT) is a genetic disorder of the glycoprotein IIb/IIIa complex on the platelet surface, which results in faulty platelet aggregation and diminished clot retraction.⁶ The exact incidence is unknown but is estimated at approximately 1:1,000,000 individuals. Most individuals are diagnosed before 5 years of age. Prophylactic therapy is not needed, but treatment is necessary for surgical procedures and to control acute bleeding episodes. Platelet transfusion is considered standard therapy if local measures are inadequate to control bleeding. NovoSeven RT has been successfully used in patients who are refractory to platelet transfusions or to avoid the need for transfusion. **Congenital Factor VII deficiency** is a rare autosomal recessive disorder affecting an estimated 1:300,000 to 1:500,000 individuals.^{7,8} NovoSeven RT is the standard treatment for this condition.

Of note, off-label use of NovoSeven RT in the general population has been suggested in a variety of acute bleeding scenarios (e.g., trauma, intracranial hemorrhage). A 2012 Cochrane Review concluded that the effectiveness of recombinant activated Factor VIIa as a general hemostatic drug in non-hemophiliac patients remains unproven and that use outside its licensed indications should be limited to clinical trials.⁹ Various reviews and clinical practice guidelines concur that the evidence is insufficient to support use of NovoSeven RT as a hemostatic agent outside of its labeled uses.¹⁰⁻¹²

Guidelines

The National Hemophilia Foundation (NHF) Medical and Scientific Advisory Council (MASAC) has recommendations concerning products used for the treatment of hemophilia and other bleeding disorders.² NovoSeven RT is supported as a treatment option for inherited hemophilia A or B with inhibitors, acquired hemophilia A, and Factor VII deficiency (Glanzmann's thrombasthenia is not addressed in the guidelines). MASAC recommendations (2013) also state that NovoSeven RT and FEIBA have demonstrated efficacy and safety for prophylactic use for patients with inhibitors in hemophilia A and hemophilia B.¹³

POLICY STATEMENT

Prior authorization is recommended for prescription benefit coverage of NovoSeven RT. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with NovoSeven RT as well as the monitoring required for adverse events and long-term efficacy, approval requires these agents to be prescribed by or in consultation with a physician who specializes in the condition being treated.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of NovoSeven RT is recommended in those who meet the following criteria:

FDA-Approved Indications

- 1. Congenital Factor VII Deficiency.** Approve for 1 year if NovoSeven RT is prescribed by or in consultation with a hemophilia specialist.
- 2. Glanzmann's Thrombasthenia.** Approve for 1 year if NovoSeven RT is prescribed by or in consultation with a hematologist.
- 3. Hemophilia A, Acquired.** Approve for 1 year if NovoSeven RT is prescribed by or in consultation with a hemophilia specialist.
- 4. Hemophilia A with Inhibitors.** Approve for 1 year if NovoSeven RT is prescribed by or in consultation with a hemophilia specialist.
- 5. Hemophilia B with Inhibitors.** Approve for 1 year if NovoSeven RT is prescribed by or in consultation with a hemophilia specialist.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

NovoSeven RT has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. Rationale for non-coverage for these specific conditions is provided below. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval.)

- 1. Bleeding Associated with Liver Disease.** Randomized trials have failed to show benefit of NovoSeven RT in controlling upper gastrointestinal bleeding and variceal bleeding in patients with advanced liver disease.^{14,15} American Association for the Study of Liver Disease guidelines for portal hypertensive bleeding in cirrhosis (2016) state that recombinant Factor VIIa should not be used to correct coagulopathy in this scenario.¹⁶
- 2.** Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. NovoSeven® RT for intravenous use [prescribing information]. Plainsboro, NJ: Novo Nordisk; January 2019.
 2. Adam MP, Ardinger HH, Pagon RA, et al. GeneReviews®: Hemophilia A [Internet]. Updated June 22, 2017. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK1404/>. Accessed on June 6, 2019.
 3. Konkle BA, Hutson J, Fletcher SN. GeneReviews®: Hemophilia B [Internet]. Updated June 15, 2017. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK1495/>. Accessed on June 6, 2019.
 4. MASAC (Medical and Scientific Advisory Council) recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders (Revised April 2018). MASAC Document #253. Adopted on April 23, 2018. Available at: <https://www.hemophilia.org/node/3675>. Accessed on June 4, 2019.
 5. About bleeding disorders: what are the treatment options for inhibitors? World Federation of Hemophilia. Updated March 2018. Available at: <https://www.wfh.org/en/page.aspx?pid=652>. Accessed on June 5, 2019.
 6. Solh T, Botsford A, Solh M. Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options. *J Blood Med.* 2015;6:219-227.
 7. Rare disease database: factor VII deficiency. National Organization for Rare Disorders. Updated 2018. Available at: <https://rarediseases.org/rare-diseases/factor-vii-deficiency/>. Accessed on June 6, 2019.
 8. Napolitano M, Giansily-Blaizot M, Dolce A, et al. Prophylaxis in congenital factor VII deficiency: indications, efficacy, and safety. Results from the Seven Treatment Evaluation Registry (STER). *Haematologica.* 2013;98(4):538-44.
 9. Simpson E, Lin Y, Stanworth S, et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. *Cochrane Database Syst Rev.* 2012;3:CD005011.
 10. Cannon JW, Khan MA, Raja AS, et al. Damage control resuscitation in patients with severe traumatic hemorrhage: a practice management guideline from the Eastern Association for the Surgery of Trauma. *J Trauma Acute Care Surg.* 2017;82(3):605-617.
 11. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al.; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* 2015;46(7):2032-60.
 12. Yank V, Tuohy CV, Logan AC, et al. Comparative effectiveness of in-hospital use of recombinant factor VIIa for off-label indications vs. usual care [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US). Updated May 2010. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK98697/>. Accessed on July 3, 2019.
 13. MASAC (Medical and Scientific Advisory Council) recommendation regarding prophylaxis with bypassing agents in patients with hemophilia and high titer inhibitors. MASAC Document #220. Adopted on October 6, 2013. Available at: <https://www.hemophilia.org/sites/default/files/document/files/masac220.pdf>. Accessed on June 6, 2019.
 14. Bosch J, Thabut D, Bendtsen F, et al; European Study Group on rFVIIa in UGI Haemorrhage. Recombinant Factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. *Gastroenterology.* 2004;127(4):1123-30.
 15. Bosch J, Thabut D, Albillos A, et al; International Study Group on rFVIIa in UGI Hemorrhage. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. *Hepatology.* 2008;47(5):1604-14.
 16. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. *Hepatology.* 2017;65(1):310-335. Available at: <https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.28906>. Accessed on July 3, 2019.
-